Diabetes dual agonist drugs for Parkinson’s

Glucagon-like peptide 1 receptor (or GLP-1R) agonists are recognised as a frontline treatment for diabetes. Researchers have recently been developing the next generation of treatment for diabetes which target GLP-1R and another protein called gastric inhibitory polypeptide (or GIP) at the same time. These combination…


GCase and Parkinson’s: a new perspective

Recently researchers have provided new insights into how small defects in a region of DNA called the GBA gene could be affecting cell biology leading to Parkinson’s.


News Research news

Clinical results from Enterin trial

Biotech company Enterin has announced the results of their phase 2 clinical trial of ENT-01 indicating that it had a positive benefit on the gut symptoms associated with Parkinson’s.


News Research news

The mannitol pilot study results

The findings of a randomised, blinded clinical trial of the sweetener mannitol have been published. The results indicate that the molecule is safe and tolerable, but the study has not replicated the benefits that had previously been reported.


News Research news

Exercise and Parkinson’s

It is a well-known fact that exercise is important for our general wellbeing. Recently, there has been a lot of new research published indicating that exercise could also potentially improve the lives of people with Parkinson’s. In late 2019, the results of a clinical trial…